Clinical activity of fulvestrant in metastatic breast cancer previously treated with endocrine therapy and/or chemotherapy
Mi Hwa Heo, Hee Kyung Kim, Hansang Lee, Ji-Yeon Kim, Jin-Seok Ahn, Young-Hyuck Im, Yeon Hee Park
Korean J Intern Med. 2019;34(5):1100-1106.   Published online 2018 Mar 16     DOI: https://doi.org/10.3904/kjim.2017.226
Citations to this article as recorded by Crossref logo
Efficacy of fulvestrant and capecitabine as maintenance therapy in patients with HR +/HER2 − metastatic breast cancer benefited from first-line chemotherapy
Qing Liu, Lingyan Yu, Zhiwen Zeng, Zhangyun Li
Naunyn-Schmiedeberg's Archives of Pharmacology.2026; 399(5): 7631.     CrossRef
CT-defined sarcopenia and outcomes in HR+/HER2− metastatic breast cancer treated with CDK4/6 inhibitors
Zeynep Alaca Topcu, Zehra Sucuoglu Isleyen, Ismail Yurtsever, Bugra Oztosun, Engin Erdemoglu, Mehmet Besiroglu, Haci Mehmet Turk, Mahmut Gumus
Frontiers in Medicine.2026;[Epub]     CrossRef
A review of therapeutic agents for breast cancer with potentially radiosensitizing properties
Zhongwei Zhang, David Lim, Zhihui Feng
Radiation Medicine and Protection.2024; 5(2): 75.     CrossRef
Role of sex hormones in modulating breast and ovarian cancer associated pain
Melissa C. McHann, Henry L. Blanton, Josée Guindon
Molecular and Cellular Endocrinology.2021; 533: 111320.     CrossRef